Effect of insulin resistance on serum paraoxonase activity in a nondiabetic population

Metabolism: Clinical and Experimental

Volumn 50, Issue 7, 2001, Pages 805-811

  Yamada, Atsuko ^a   Shoji, Tetsuo ^a   Tahara, Hideki ^a   Emoto, Masanori ^a   Nizhizawa, Yoshiki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDESULFONE; ARYLDIALKYLPHOSPHATASE; ESTERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LIPID PEROXIDE; LOW DENSITY LIPOPROTEIN; ORGANOPHOSPHORUS COMPOUND; PARAOXON;

ADULT; AGE; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY MASS; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME POLYMORPHISM; FEMALE; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; HYDROLYSIS; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; JAPAN; LIPID STORAGE; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; SEX DIFFERENCE;

EID: 0034921701     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2001.24215     Document Type: Article

References (46)

1. Human and rabbit paraoxonases: Purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification
2. Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats
3. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase
4. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification
5. HDL, its enzymes and its potential to influence lipid peroxidation
6. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis
7. Paraoxonase and coronary heart disease
8. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations
9. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin
10. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression
11. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease
12. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes
13. Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus
14. A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese
15. Genetic polymorphism of paraoxonase and the risk of coronary heart disease
16. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease
17. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease
18. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study
19. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns
20. The gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients
21. Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients
22. No association of paraoxonase gene polymorphism with atherosclerosis or Alzheimer's disease
23. Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q-R genetic polymorphism
24. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus
25. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins
26. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus
27. Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus
28. The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia
29. Decrease of serum paraoxonase activity in chronic renal failure
30. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease
31. Insulin resistance in uremia
32. Correlation between the intima-media thickness of the carotid artery and aortic pulse-wave velocity in patients with type 2 diabetes. Vessel wall properties in type 2 diabetes
33. High-resolution B-mode ultrasonography in evaluation of atherosclerosis in uremia
34. Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients
35. Report of the expert committee on the diagnosis and classification of diabetes mellitus
36. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man
37. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas
38. The human serum paraoxonase polymorphism: Identification of phenotypes by their response to salts
39. The molecular basis of the human serum paraoxonase activity polymorphism
40. +/dextran sulfate in its enzymic measurement
41. Paraoxon hydrolysis in human serum mediated by a genetically variable arylesterase and albumin
42. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein
43. Depressed plasma platelet-activating factor acetylhydrolase in patients presenting with acute myocardial infarction
44. Serum paraoxonase after myocardial infarction
45. Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity: Effect of hyperinsulinemia and lovastatin treatment